SAN DIEGO, October 25 — Aclara BioSciences and Third Wave Technologies on Thursday announced a collaboration to develop and commercialize multiplexed gene expression research products that couple Aclara’s eTag sequence-labeling technology with Third Wave's Invader platform.
The companies said that their combined technologies would enable customers to profile many genes simultaneously in a single reaction directly from crude cell lysates, without the need for sample prep or PCR.
The first products from the collaboration, to become commercially available immediately through an early access program, will detect and quantify the expression levels of clinically relevant genes, including cytokine and cytochrome P450 genes. Commercialization will begin immediately through an early access program.
Aclara CEO Joseph Limber said that the Invader platform was appealing for its ability to simultaneously profile many genes directly from crude cell lysates, without sample prep or thermocycling and with superior quantitation and specificity.
The companies said they would also explore the potential for combining their technologies for new genotyping applications.